1. Home
  2. HOLX vs EXAS Comparison

HOLX vs EXAS Comparison

Compare HOLX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hologic Inc.

HOLX

Hologic Inc.

HOLD

Current Price

$75.34

Market Cap

16.6B

Sector

Health Care

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$103.27

Market Cap

19.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOLX
EXAS
Founded
1985
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Electronics
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6B
19.7B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
HOLX
EXAS
Price
$75.34
$103.27
Analyst Decision
Hold
Hold
Analyst Count
13
18
Target Price
$77.89
$85.64
AVG Volume (30 Days)
2.5M
2.1M
Earning Date
04-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.32
EPS
0.79
N/A
Revenue
$4,100,500,000.00
$4,144,000.00
Revenue This Year
$4.74
$15.18
Revenue Next Year
$5.03
$12.46
P/E Ratio
$95.38
N/A
Revenue Growth
1.74
N/A
52 Week Low
$51.90
$38.88
52 Week High
$75.49
$103.87

Technical Indicators

Market Signals
Indicator
HOLX
EXAS
Relative Strength Index (RSI) 61.49 65.17
Support Level $74.53 $101.12
Resistance Level N/A $103.87
Average True Range (ATR) 0.21 0.33
MACD 0.04 -0.13
Stochastic Oscillator 85.89 66.15

Price Performance

Historical Comparison
HOLX
EXAS

About HOLX Hologic Inc.

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: